Vimta Labs Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Vimta Labs Ltd trades at ₹559, in a downtrend and 25 weeks into that stage. That is +6.8% against its own 200-day average. It sits at 33% of a 52-week range of ₹401 to ₹877. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 16 straight weeks.

Today the stock is in a downtrend — week 25 of stage 4. At ₹559 it trades +6.8% versus its 200-day average and sits at 33% of its 52-week range (₹401–₹877).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +1,492% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 16 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 86th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Vimta Labs Ltd trades at 41.9× P/E, at the pricey end of its own range (86th percentile). Its long-run median P/E is 26.2×, measured across 6.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 41.9× is at the pricey end of its own range (86th percentile), against a long-run median of 26.2× measured over 6.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −14.8% against a +6.4% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +29.8%/yr price move, ~+14.1%/yr came from earnings growth and ~+15.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources disagree by up to 64% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Vimta Labs Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 8 quarters ago at −16.7% and has held its recovery at +120.0% (single-quarter readings), ROCE holding at 18.0%. The read is built from 9 quarters across 3 curves, on partial evidence.

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

44.4/100 — rank 9 of 9 in Diagnostics · 45% evidence confidence · provisional, ranked below fully-evidenced peers

Vimta Labs Ltd scores 44.4 out of 100 against the 9 companies it is compared with in Diagnostics, ranking 9. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 17.5 + 14.7 + 7.6 + 4.6 = 44.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Vimta Labs Ltd reported ₹90.0 Cr of revenue in the Dec 24 quarter, +20.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 15.1% a year. The last full year, FY24, came in at ₹318 Cr. The last four reported quarters add to ₹330 Cr.

Vimta Labs Ltd reported ₹90.0 Cr of revenue in the Dec 24 quarter, +20.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 15.1% a year. The last full year, FY24, came in at ₹318 Cr. The last four reported quarters add to ₹330 Cr.

FY24 revenue came in at ₹318 Cr (+0.0% on the year), capping 4 years at 15.1% compound. The latest quarter (Dec 24) printed ₹90.0 Cr, +20.0% year on year — the 2nd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +9.2% growth against the decade's 15.1% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +7.8% over the last 4 quarters against +3.2%/yr over the last 8 — accelerating; TTM profit +48.8% vs +13.9%/yr — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: 37.0% this quarter (+5.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Vimta Labs Ltd's operating margin is 37.0% in the Dec 24 quarter, +5.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.0% to 30.0%. The current quarter is running above every full year in that window.

Vimta Labs Ltd's operating margin is 37.0% in the Dec 24 quarter, +5.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.0% to 30.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 37.0%, +5.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 17.0%–30.0%.

Why the margin moved: operating margin went +4.7 pp year on year while gross margin went −2.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins held — did that reach the bottom line? Next: profit +120.0% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Vimta Labs Ltd earned ₹22.0 Cr of net profit in the Dec 24 quarter, +120.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY24 profit was ₹41.0 Cr. The 4-year compound rate is 55.6%. That is 24.4% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr.

Vimta Labs Ltd earned ₹22.0 Cr of net profit in the Dec 24 quarter, +120.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY24 profit was ₹41.0 Cr. The 4-year compound rate is 55.6%. That is 24.4% of the quarter's revenue. The same quarter a year earlier earned ₹10.0 Cr.

Dec 24 profit was ₹22.0 Cr, +120.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY24 printed ₹41.0 Cr (−14.6%), and the 4-year compound rate is 55.6%.

Why profit moved: revenue contributed +20.0% and the margin +5.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +65.6% vs revenue +9.2%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

→ Profit rose — but did the cash follow? Next: 160% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 160% of Vimta Labs Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY24 that was ₹61.0 Cr of operating cash against ₹41.0 Cr of profit. After ₹77.0 Cr of capital spending, ₹−16.0 Cr was left as free cash.

FY24: operating cash of ₹61.0 Cr against reported profit of ₹41.0 Cr, leaving free cash of ₹−16.0 Cr after ₹77.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 160% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 160%: the cash cycle stretched 32 days between FY20 and FY24 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹166 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Vimta Labs Ltd's cash conversion cycle runs 223 days in FY24, up from 191 days in FY20. Capital spending ran ₹166 Cr over the last 3 years. At FY24 sales of ₹318 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹194 Cr sits inside the business at any moment.

FY24: debtors at 100 days, inventory at 185 days — roughly 6.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 223 days, looser than FY20's 191.

The full loop: cash goes out to suppliers and production on day 0; stock waits 185 days to sell; customers pay about 100 days after that; and suppliers themselves are paid at 62 days — netting out to the 223-day cycle.

In money terms: at FY24 sales of ₹318 Cr, each day of the cycle holds about ₹0.9 Cr — so the 223-day loop keeps roughly ₹194 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹166 Cr over the last 3 fiscal years against ₹88.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹59.0 Cr (FY24) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 18%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Vimta Labs Ltd earns a ROCE of 18% in FY24. That is up from a trough of 14% in FY21. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 12.9% net margin on 0.80× asset turns.

FY24 ROCE is 18%, recovered from a FY21 trough of 14% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY24): 12.9% net margin × 0.80× asset turns × 1.25× balance-sheet leverage ≈ 12.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 64% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.06.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Vimta Labs Ltd carries ₹19.0 Cr of borrowings against ₹319 Cr of equity in FY24, a debt-to-equity of 0.06. Operating profit covers the interest bill 44×. Over 4 years borrowings went from ₹33.0 Cr to ₹19.0 Cr. Capital spending ran ₹166 Cr across the last 3 of those years.

FY24: borrowings of ₹19.0 Cr against equity of ₹319 Cr — a debt-to-equity of 0.06. Operating profit covers the interest bill 44×. Over 4 years borrowings went from ₹33.0 Cr to ₹19.0 Cr while capital spending ran ₹166 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 64% on reported income across 13 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

→ Who owns this, and are they adding or leaving? Next: Promoters cut 1.2 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 1.2 points of Vimta Labs Ltd over 8 quarters, the biggest move on the register. That takes promoters to 35.7% of the company. Domestic institutions moved −1.1 points over the same window, to 0.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −1.2 points over 8 quarters to 35.7%; Domestic institutions: −1.1 points over 8 quarters to 0.4%; Foreign institutions: −0.8 points over 8 quarters to 4.4%.

🚨 Why the register moved: promoters drove it (−1.2 points), alongside domestic institutions (−1.1 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Vimta Labs Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions